Drugs / NEDISERTIB
NEDISERTIB
Trials 18
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-06-22 | Telix Pharmaceuticals (Innovations) Pty Limited | Results Telix to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI telixpharma.com ↗
Addition of DNA dependent protein kinase (DNA-PK) inhibitor peposertib enhances efficacy of 177Lu-based radioimmunotherapy in pre-clinical models of prostate and renal cell carcinoma |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-06-22 | Telix Pharmaceuticals (Innovations) Pty Limited | Telix to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI telixpharma.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEDISERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297629 ↗ |
| Known as | M3814 | “Participants received M3814 PiC or hot melt extrusion (HME) tablet orally once daily in combination with etoposide (intravenously) and cisplatin for 6 cycles with each cycle...” NCT03116971 ↗ |
| Known as | MSC2490484A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02316197 ↗ |
| Known as | Peposertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02813135 ↗ |
| Action | Inhibit | “an Inhibitor of a DNA-dependent Protein Kinase” NCT02516813 ↗ |
| Modality | Small molecule | — CHEMBL4297629 ↗ |
| Route | Oral | “Participants received MSC2490484A capsules 100 milligram (mg) orally, once daily (QD) from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable...” NCT02316197 ↗ |